NO974194D0 - Forbedringer i, eller vedrörende, organiske sammensetninger - Google Patents

Forbedringer i, eller vedrörende, organiske sammensetninger

Info

Publication number
NO974194D0
NO974194D0 NO974194A NO974194A NO974194D0 NO 974194 D0 NO974194 D0 NO 974194D0 NO 974194 A NO974194 A NO 974194A NO 974194 A NO974194 A NO 974194A NO 974194 D0 NO974194 D0 NO 974194D0
Authority
NO
Norway
Prior art keywords
organic compositions
granules
andb
comprisinga
carbomer
Prior art date
Application number
NO974194A
Other languages
English (en)
Norwegian (no)
Other versions
NO974194L (no
Inventor
Peter Williams Dettmar
Paul Andrew Dickson
Frank Chadwick Hampson
Ian Gordon Jolliffe
William Peers
Original Assignee
Reckitt & Colmann Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt & Colmann Prod Ltd filed Critical Reckitt & Colmann Prod Ltd
Publication of NO974194D0 publication Critical patent/NO974194D0/no
Publication of NO974194L publication Critical patent/NO974194L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO974194A 1995-03-13 1997-09-11 Forbedringer i, eller vedrörende, organiske sammensetninger NO974194L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9505032.4A GB9505032D0 (en) 1995-03-13 1995-03-13 Improvements in or relating to organic compositions
PCT/GB1996/000514 WO1996028141A1 (en) 1995-03-13 1996-03-05 Improvements in or relating to organic compositions

Publications (2)

Publication Number Publication Date
NO974194D0 true NO974194D0 (no) 1997-09-11
NO974194L NO974194L (no) 1997-09-11

Family

ID=10771122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974194A NO974194L (no) 1995-03-13 1997-09-11 Forbedringer i, eller vedrörende, organiske sammensetninger

Country Status (21)

Country Link
US (1) US6306789B1 (de)
EP (1) EP0814771B1 (de)
JP (1) JPH11501652A (de)
KR (1) KR19980702970A (de)
CN (1) CN1126533C (de)
AT (1) ATE212539T1 (de)
AU (1) AU712464B2 (de)
BR (1) BR9607234A (de)
CZ (1) CZ274497A3 (de)
DE (1) DE69618934T2 (de)
ES (1) ES2167546T3 (de)
GB (2) GB9505032D0 (de)
HK (1) HK1011291A1 (de)
HU (1) HUP9900800A3 (de)
MX (1) MX9706992A (de)
NO (1) NO974194L (de)
NZ (1) NZ302741A (de)
PL (1) PL184407B1 (de)
TR (1) TR199700943T1 (de)
WO (1) WO1996028141A1 (de)
ZA (1) ZA962012B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1203846C (zh) * 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
GB9809347D0 (en) * 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
IN190017B (de) * 1999-01-25 2003-05-31 Panacea Biotech Ltd
JP2004513975A (ja) 2000-12-05 2004-05-13 マクグレゴール アレキサンダー 作用物質の制御放出のための静水圧デリバリシステム
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP2942053A1 (de) 2007-07-06 2015-11-11 Lupin Limited Pharmazeutische Zusammensetzungen zur Wirkstoffverabreichung im Magen-Darm-Trakt
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
ES2729925T3 (es) 2007-11-13 2019-11-07 Meritage Pharma Inc Composiciones de corticosteroides
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
LT2328553T (lt) 2008-08-20 2020-09-10 The Regents Of The University Of California Kortikosteroidai, skirti virškinimo trakto uždegiminių ligų gydymui
JP6552115B2 (ja) * 2013-03-15 2019-07-31 クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーCook Medical Technologies Llc 消化管病変を治療するための接着性医療製品及び方法
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US11452798B2 (en) 2017-09-27 2022-09-27 Cook Medical Technologies Llc Crosslinking submucosal injectate system
JP7497289B2 (ja) 2018-01-09 2024-06-10 ドンペ ファーマシューティシ エス.ピー.エー. 成長因子耳用製剤
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CN114904007B (zh) * 2022-04-24 2024-04-05 南京紫鸿生物科技有限公司 一种提高卡波姆的堆积密度的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60237054A (ja) 1984-05-10 1985-11-25 Nippon Kayaku Co Ltd アミノ酸の晶析法
GB8428952D0 (en) 1984-11-16 1984-12-27 Beecham Group Plc Formulations
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
EP0297866A3 (de) 1987-07-01 1989-12-13 The Boots Company PLC Arzneimittel
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
DE69424487T2 (de) * 1993-09-09 2001-01-18 Takeda Chemical Industries, Ltd. Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff

Also Published As

Publication number Publication date
HK1011291A1 (en) 1999-07-09
NZ302741A (en) 1999-08-30
ATE212539T1 (de) 2002-02-15
DE69618934T2 (de) 2002-09-12
AU4886896A (en) 1996-10-02
HUP9900800A3 (en) 2001-02-28
JPH11501652A (ja) 1999-02-09
DE69618934D1 (de) 2002-03-14
WO1996028141A1 (en) 1996-09-19
HUP9900800A2 (hu) 1999-07-28
ES2167546T3 (es) 2002-05-16
GB9505032D0 (en) 1995-05-03
US6306789B1 (en) 2001-10-23
PL184407B1 (pl) 2002-10-31
CN1126533C (zh) 2003-11-05
PL322065A1 (en) 1998-01-05
KR19980702970A (ko) 1998-09-05
MX9706992A (es) 1997-11-29
CZ274497A3 (cs) 1998-03-18
AU712464B2 (en) 1999-11-04
GB9604678D0 (en) 1996-05-01
NO974194L (no) 1997-09-11
GB2298790B (en) 1999-06-30
ZA962012B (en) 1996-09-26
EP0814771B1 (de) 2002-01-30
GB2298790A (en) 1996-09-18
EP0814771A1 (de) 1998-01-07
CN1178458A (zh) 1998-04-08
TR199700943T1 (xx) 1998-02-21
BR9607234A (pt) 1997-11-11

Similar Documents

Publication Publication Date Title
NO974194D0 (no) Forbedringer i, eller vedrörende, organiske sammensetninger
AU725283B2 (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
BR0311530A (pt) Compostos e método de liberação para droga transmucosal e para crio-proteção
NO20001567L (no) Bioadhesive sammensetninger og fremgangsmÕter for topisk administrering av aktive midler
DE69732412D1 (de) Polares bukkales spray
CA2361716A1 (en) Method of preparing alkylated salicylamides
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
GB0122318D0 (en) Organic compounds
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
IL186655A0 (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DE60331648D1 (de) Puffende orale darreichungsformen
WO2003063823A3 (en) Osmotic delivery system
WO2004021985A3 (en) Verifiable absorption drug delivery form based on cyclodextrins
CA2214979A1 (en) Improvements in or relating to organic compositions
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
RU2001128736A (ru) Способ нормализации воспроизводительной функции коров
WO2003040316A3 (en) Selective elimination of cd52+ cells and uses thereof
文案 et al. SHINO FOR
GT199700143A (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application